Arcus Biosciences, Inc. (RCUS)
| Market Cap | 3.80B +264.8% |
| Revenue (ttm) | 236.00M +67.4% |
| Net Income | -369.00M |
| EPS | -3.23 |
| Shares Out | 125.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,559,832 |
| Open | 28.68 |
| Previous Close | 28.80 |
| Day's Range | 28.00 - 31.44 |
| 52-Week Range | 7.91 - 31.44 |
| Beta | 0.84 |
| Analysts | Strong Buy |
| Price Target | 35.75 (+18.18%) |
| Earnings Date | Aug 5, 2026 |
About RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2α inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in... [Read more]
Financial Performance
In 2025, Arcus Biosciences's revenue was $247.00 million, a decrease of -4.26% compared to the previous year's $258.00 million. Losses were -$353.00 million, 24.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for RCUS stock is "Strong Buy." The 12-month stock price target is $35.75, which is an increase of 18.18% from the latest price.
News
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...
Arcus Biosciences Transcript: AGM 2026
The meeting confirmed quorum and addressed three proposals: director elections, auditor ratification, and executive compensation, all of which passed. No questions were raised, and final voting results will be published in a Form 8-K.
Arcus Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Casdatifan is positioned as a potential backbone therapy for RCC, with multiple studies across all lines of treatment and significant upcoming data readouts. The company maintains strong financials, robust I&I pipeline, and a strategy to retain full commercial rights while leveraging clinical collaborations.
Arcus Biosciences Slides: FY 2026
Arcus Biosciences has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 9, 2026.
Arcus Biosciences initiated with an Outperform at LifeSci Capital
LifeSci Capital analyst Charles Zhu initiated coverage of Arcus Biosciences (RCUS) with an Outperform rating and $46 price target
Arcus enters clinical trial collaboration, supply agreement with Bristol Myers
Arcus Biosciences (RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (BMY). Under the agreement, Arcus will supply casdatifan, the company’s investigational...
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient...
Arcus Biosciences assumed with a Buy at Truist
Truist assumed coverage of Arcus Biosciences (RCUS) with a Buy rating and a price target of $35, up from $30. The firm views the setup as “increasingly compelling,” with upside…
Arcus Biosciences price target raised to $22 from $20 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Arcus Biosciences (RCUS) to $22 from $20 and keeps an Equal Weight rating on the shares.
Arcus Biosciences Earnings Call Transcript: Q1 2026
Full ownership of casdatifan enables rapid advancement in RCC, with late-stage trials progressing and a strong financial position supporting expansion into immunology. Multiple data readouts and new clinical entries are expected in 2026, with a cash runway into 2028.
Arcus Biosciences Slides: Q1 2026
Arcus Biosciences has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Arcus Biosciences Earnings release: Q1 2026
Arcus Biosciences released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Arcus Biosciences Quarterly report: Q1 2026
Arcus Biosciences has published its Q1 2026 quarterly earnings report on May 5, 2026.
Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...
Arcus Biosciences rises 12.2%
Arcus Biosciences (RCUS) is up 12.2%, or $2.98 to $27.50.
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient...
Merck setback has positives and negatives for Arcus Biosciences, says BofA
BofA notes Merck (MRK) and Eisai (ESAIY) announced that the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with advanced clear cell renal cell car...
Merck study miss not a read for Arcus, says H.C. Wainwright
H.C. Wainwright says Merck’s (MRK) LITESPARK-012 trial miss in clear cell renal cell carcinoma is not a read to Arcus Biosciences’ (RCUS) casdatifan. Arcus is planning to evaluate a different…
Arcus Biosciences Proxy statement: Proxy filing
Arcus Biosciences filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Arcus Biosciences Proxy statement: Proxy filing
Arcus Biosciences filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Arcus Biosciences discontinues Star-121 study with Gilead due to futility
In a regulatory filing, Arcus Biosciences (RCUS) announced the discontinuation of the Phase 3 STAR-121 study, which is being conducted in collaboration with Gilead Sciences (GILD), due to futility. ST...
Arcus Biosciences price target lowered to $47 from $49 at Leerink
Leerink lowered the firm’s price target on Arcus Biosciences to $47 from $49 and keeps an Outperform rating on the shares. The firm sees the end of Arcus’ (RCUS) research…
Wedbush raises Arcus Biosciences price target to $41, adds to Best Ideas List
Wedbush raised the firm’s price target on Arcus Biosciences (RCUS) to $41 from $37 and keeps an Outperform rating on the shares. The firm is also adding the stock to…
Arcus Biosciences Transcript: Leerink Global Healthcare Conference 2026
Casdatifan shows superior efficacy and durability over belzutifan in RCC, with higher response rates, longer PFS, and robust biomarker correlation. Safety is comparable, and ongoing ARC-20 and PEAK-1 studies will provide key data on combinations and sequencing strategies.